H.C. Wainwright keeps USD 9.00 target for NovaBridge Biosciences stock

Published on 10/15/2026 at 20:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 12, 2026. NovaBridge Biosciences stock costs USD 1.29 on October 15, 2026, up 0.78 percent on Nasdaq.

Analyst target and trading

H.C. Wainwright maintained its Buy rating and USD 9.00 target on October 13, 2026.
NovaBridge Biosciences stock was 67.59 percent lower year to date on October 15, 2026.
NovaBridge Biosciences stock cost USD 1.29 at 1:01 p.m. EDT on October 15, 2026, 0.78 percent above the Nasdaq prior close of October 14, 2026.
NovaBridge Biosciences is scheduled to report third-quarter results on November 12, 2026.

NBP, US44975P1030, Illustration mit AI erstellt.

H.C. Wainwright maintained a Buy rating and a USD 9.00 price target for NovaBridge Biosciences on October 13, 2026, according to Markets Insider. The target stands 597.67 percent above the USD 1.29 Nasdaq price. Barron's also lists USD 9.00 as the average target from two ratings. On October 15, 2026 at 1:01 p.m. EDT, NovaBridge Biosciences stock was at USD 1.29 on Nasdaq, up 0.78 percent from the Nasdaq close of October 14, 2026.

Year-to-date decline reaches 67.59 percent

The price target is a sharp contrast with the stock's market performance. MarketWatch lists a 67.59 percent decline for the year to date through October 15, 2026. The same quote page gives a 52-week range of USD 1.26 to USD 6.79, placing the current price USD 0.03 above the low and USD 5.50 below the high.

NovaBridge describes itself as a clinical-stage biotechnology company developing medicines in oncology and ophthalmology, including givastomig and VIS-101, on its investor-relations page. The company identifies its listing as Nasdaq: NBP and its business as a global biotechnology platform.

Results date is November 12

Barron's lists November 12, 2026 as the expected reporting date for third-quarter results. It also lists March 31, 2027 for full-year 2026 results, giving investors two dated milestones beyond the current quote.

Comparison with peers

NBP (Nasdaq, USD): plus 0.78 percent, market capitalization USD 148.5 million.

Johnson & Johnson (NYSE, USD): plus 0.85 percent, market capitalization USD 611.9 billion.

Pfizer (NYSE, USD): plus 1.66 percent, market capitalization USD 166.5 billion.

Price and valuation markers

MarketWatch lists a market capitalization of USD 148.5 million and volume of 303,810 shares for October 15, 2026, against an average volume of 384,050 shares. The quote page lists no dividend yield or price-to-earnings ratio, so the analyst target and the upcoming reporting date provide the clearest dated reference points.

The stock's latest Nasdaq indication was USD 1.29 on October 15, 2026 at 1:01 p.m. EDT, 0.78 percent above the Nasdaq close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of NovaBridge Biosciences stock.